DRIVIN G ROWTH - Dr. Reddy's

20
custom chemical
services
COST-EFFECTIVE QUALITY RESEARCH
URRENTLY IT TAKES 10-15
C
years for a drug to traverse from
laboratory to market. The expenses
during this journey amount to approximately
US$ 800 and more. The sequencing of the
human genome has increased expectations
from the pharmaceutical sector to accelerate
the entry of drugs into the market. In this
scenario, companies are beginning to focus
on decreasing the drug development
timeline and expenses by introducing
effective technologies as well as outsourcing
strategies. Dr. Reddy’s has taken an
initiative to stay ahead in this game.
Standing evidence is the Technology
Development Centre(TDC) at Miyapur. An
extension of the process development
facilities and services, TDC is a part of the
Custom Chemical Services, an independent
business unit of Dr. Reddy’s Group.
SBU Custom Chemical Services(CCS)
provides services in Custom Synthesis,
Contract Manufacture and Supply of Key
Intermediates. The objective of CCS is be
the preferred partner for innovator
companies and providing a complete range
of chemical services that are necessary to
take their innovations to the market
speedily and more efficiently. The focus of
this business unit is to leverage on skills in
process development, analytical
development and cGMP manufacture to
cater to various needs of innovator
companies.
CCS has a competent team comprising
research scientists, organic chemists, process
engineers and project coordinators
dedicated to offering customised solutions
to the customer’s needs, from the preclinical
stage until commercialisation. Feasibility
responses are provided promptly ensuring
that the customer is given rapid feedback
on enquiries.
Over the years, CCS has built an
extensive knowledge base in multi-step
organic synthesis, polymorphism and in the
handling of specialised technologies such as
stereoselective chemistry, chemical
resolution, amino-acid and carbohydrate
chemistry to name a few.
Dedicated resources are backed by the
flexibility to produce quantities with scales
ranging from initial gram requirements and
kilograms to multitons. CCS has dedicated
to cGMP capacities to meet the outsourcing
requirements for key intermediates and
major bulk actives. Dr. Reddy’s has three
cGMP pilot plants and six USFDA inspected
facilities, with a history of numerous
European and US regulatory submissions.
CCS is well equipped to address all kinds of
synthesis needs and is backed by complete
DR. REDDY’S LABORATORIES LTD. | CUSTOM CHEMICAL SERVICES | ANNUAL REPORT 2001-2002